Xcout IntelPhenomic AI
Phenomic AI Inc. is a biotechnology company developing novel antibody-based therapies directed against the tumor stroma to improve patient outcomes.
Subscribe to see Phenomic AI’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Phenomic AI at a glance
Phenomic AI is a biotechnology company headquartered in Canada. Its most recent funding round, Seed, raised $6M in October 2020. Xcout tracks 5 named people at Phenomic AI, including GIRISH AAKALU (CEO).
Phenomic AI leadership
- GIRISH AAKALUCEO
- Mike BriskinCSO, Chair SAB
- Sam CooperCTO
- Oren KrausCo-founder
- Chris HarveyVP of Research and Translational Development
Phenomic AI funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Phenomic AI competitors
A few of Phenomic AI's closest competitors — see the full list of competitors and alternatives →
9Bio Therapeutics is a biotechnology company that combines biology, structural engineering, and artificial intelligence to pioneer next-generation biologics for advanced cancers. The company is headquartered in Quebec, Canada.
Biolojic Design is an Israeli biotechnology company that uses computational modeling and artificial intelligence to design and engineer antibodies and other therapeutic proteins. It develops drug candidates and collaborates with pharmaceutical and biotechnology companies seeking novel biologic medicines.
Pharos iBio Co., Ltd. is a South Korean biotechnology company that uses artificial intelligence and big-data approaches for drug discovery and development. Its pipeline includes oncology candidates such as PHI-101, a FLT3 inhibitor being developed for acute myeloid leukemia and other cancers, serving patients with difficult-to-treat diseases and pharmaceutical development partners.
Prellis Biologics, Inc. is a privately held biotechnology company headquartered in Berkeley, California, within the San Francisco Bay Area. It develops human antibody therapeutics and focuses on antibody discovery leveraging AI and immune diversity.
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Atomic AI is a biotechnology research company specializing in RNA drug discovery utilizing atomic precision. Headquartered in San Francisco, California, the company combines machine learning and biology to develop advanced therapeutics.
Get Phenomic AI's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Phenomic AI in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access